Nav: Home

First-in-class YEATS inhibitors that show promise for leukemia treatment

November 06, 2018

A research team led by Dr. Xiang David Li from the Department of Chemistry at The University of Hong Kong (HKU), in collaboration with scientists from Tsinghua University in China, The Rockefeller University, and The University of Texas MD Anderson Cancer Center in the United States, developed the first chemical inhibitors against a novel therapeutic target for treatment of acute myeloid leukemia (AML), a fast-growing cancer of bone marrow and blood cells. The findings were recently published in a top-class scientific journal -- Nature Chemical Biology. A patent on the development and application of the inhibitors has been filed by Dr. Li and his team members.

Cancer is traditionally believed to be associated with genetic mutations -- changes in DNA sequence -- caused by various factors such as smoking and exposure to radiations and toxic chemicals. These adverse alterations in DNA give incorrect instructions for genes to produce their proteins, and thereby mess up normal function of a cell and make it grow and multiply uncontrollably to become cancerous. The research in the past decades has, however, revealed that DNA is not the sole player in this process. A type of proteins called histones, around which DNA is packaged, can function as master switches for gene expression -- that is, to determine which sets of genes in a cell should be "ON" or "OFF". Cancer can often be the result of these switches gone wrong.

In cells, histones carry a diverse variety of chemical marks, which contain essential information to ensure every gene to be expressed precisely -- at the right time, to the right extent. Among the key players in this mechanism of gene regulation are histone "readers", a class of proteins that recognise specific marks on histones and "translate" them by turning the expression of genes up or down accordingly. It is now believed that new therapies may be developed by targeting these readers to reset gene regulatory programs that go awry in cancer. In fact, a couple of compounds targeting histone readers have demonstrated promising results in clinical trials.

At the centre of Dr. Li's current research is a new class of histone readers, which share a characteristic structural domain called YEATS. It was recently uncovered that ENL, a YEATS domain-containing protein, specifically 'reads' a histone mark called acetylation, resulting in the faulty activation of cancer-promoting genes in human acute myeloid leukemia (AML) cells. Blocking the recognition of ENL YEATS domain toward the histone mark has therefore been proposed as a new strategy for the treatment of leukemia. The key to success of this strategy is to develop chemical inhibitors targeting ENL.

"It's a big challenge," said Dr. Li. "As no chemical compound was shown to target YEATS domain, we must come up with a brand-new design." Enlightened by a crystal structure showing how a YEAT domain recognises the histone mark, Dr. Li's team designed a series of molecules to target a unique mode of interaction discovered at the recognition site. After several rounds of optimisation, an ENL inhibitor with good specificity and potency was developed. Treatment of human AML cells with this inhibitor successfully suppressed the expression of a number of cancer-promoting genes. Moreover, the inhibitor demonstrated an enhanced effect when applied together with the anti-leukemia experimental drugs, suggesting a potential combinatory therapy strategy by simultaneously inhibiting ENL and other well-characterised anti-leukemia targets. This study has therefore opened a new avenue for the treatment of this life-threatening disease.

"It is really exciting to have the first-in-class ENL inhibitors, but we still have a long way to go before we can make a drug to cure patients with acute leukemia" says Dr. Li. "We will be continuously exploring the therapeutic potential by inhibiting ENL in acute leukemia, as well as other types of cancers caused by "misreading" of ENL toward the histone marks."
-end-
About the paper

"Structure-guided development of YEATS domain inhibitors by targeting π-π-π stacking" at Nature Chemical Biology

https://www.nature.com/articles/s41589-018-0144-y

Nature Chemical Biology is a top-class international scientific journal publishing original research from the expanding community of chemical biologists.

About Dr Xiang David Li

More information about Dr Xiang David Li and his research group can be found from their group's webpage: https://xianglilab.com/

The University of Hong Kong

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Clint Smith
The killing of George Floyd by a police officer has sparked massive protests nationwide. This hour, writer and scholar Clint Smith reflects on this moment, through conversation, letters, and poetry.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Nina
Producer Tracie Hunte stumbled into a duet between Nina Simone and the sounds of protest outside her apartment. Then she discovered a performance by Nina on April 7, 1968 - three days after the assassination of Dr. Martin Luther King Jr. Tracie talks about what Nina's music, born during another time when our country was facing questions that seemed to have no answer, meant then and why it still resonates today.  Listen to Nina's brother, Samuel Waymon, talk about that April 7th concert here.